Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Biotechnology company Regeneron agreed to buy the assets of 23andMe, the DNA testing company that filed for bankruptcy in March, for $256 million. That’s just 4% of the San Francisco-based startup’s ...

Dow Jones Top Company Headlines at 7 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ... The DNA testing company would sell for a fraction of its peak valuation of $6 ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.